Fractional Flow Reserve Proves Itself Early In St. Jude’s FAME II Study
This article was originally published in The Gray Sheet
Executive Summary
St. Jude Medical’s fractional flow reserve technology gave stenting a significant enough edge in stable coronary disease patients that a monitoring board recommended stopping the study early because it would be unethical to continue to randomize patients to the optimal medical therapy control group.